HomeCompareEVKG vs JNJ

EVKG vs JNJ: Dividend Comparison 2026

EVKG yields 1000000.00% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EVKG wins by $4.7683925249533696e+36M in total portfolio value
10 years
EVKG
EVKG
● Live price
1000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.7683925249533696e+36M
Annual income
$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00
Full EVKG calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — EVKG vs JNJ

📍 EVKG pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEVKGJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EVKG + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EVKG pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EVKG
Annual income on $10K today (after 15% tax)
$85,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, EVKG beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EVKG + JNJ for your $10,000?

EVKG: 50%JNJ: 50%
100% JNJ50/50100% EVKG
Portfolio after 10yr
$2.3841962624766848e+36M
Annual income
$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

EVKG
No analyst data
Altman Z
1.8
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EVKG buys
0
JNJ buys
0
No recent congressional trades found for EVKG or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEVKGJNJ
Forward yield1000000.00%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$4.7683925249533696e+36M$30.3K
Annual income after 10y$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$4,689.40
Total dividends collected$4.7683311610149396e+36M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EVKG vs JNJ ($10,000, DRIP)

YearEVKG PortfolioEVKG Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$100,010,700$100,000,000.00$10,592$272.30+$100.00MEVKG
2$934,786,450,701$934,679,439,252.34$11,289$357.73+$934786.44MEVKG
3$8,165,787,108,578,292$8,164,786,887,076,042.00$12,123$472.89+$8165787108.57MEVKG
4$66,665,884,190,957,650,000$66,657,146,798,751,470,000.00$13,141$629.86+$66665884190957.63MEVKG
5$508,662,171,058,048,100,000,000$508,590,838,561,963,700,000,000.00$14,408$846.81+$508662171058048128.00MEVKG
6$3,627,235,248,428,489,700,000,000,000$3,626,690,979,905,457,600,000,000,000.00$16,021$1,151.60+$3.62723524842849e+21MEVKG
7$24,173,681,159,150,610,000,000,000,000,000$24,169,800,017,434,790,000,000,000,000,000.00$18,122$1,588.22+$2.417368115915061e+25MEVKG
8$150,567,402,861,454,640,000,000,000,000,000,000$150,541,537,022,614,370,000,000,000,000,000,000.00$20,930$2,228.20+$1.5056740286145463e+29MEVKG
9$876,477,100,281,847,600,000,000,000,000,000,000,000$876,315,993,160,785,800,000,000,000,000,000,000,000.00$24,792$3,191.91+$8.764771002818475e+32MEVKG
10$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$30,274$4,689.40+$4.7683925249533696e+36MEVKG

EVKG vs JNJ: Complete Analysis 2026

EVKGStock

Ever-Glory International Group, Inc., together with its subsidiaries, manufactures, supplies, and retails apparel in Mainland China, Hong Kong, Germany, the United Kingdom, Europe, Japan, and the United States. It operates through two segments, Wholesale and Retail. The company primarily offers casual wear, outerwear, and sportswear. Its products include coats, jackets, slacks, skirts, shirts, trousers, and jeans for women; vests, jackets, trousers, skiwear, shirts, coats, and jeans for men; and coats, vests, down jackets, trousers, knitwear, and jeans for children. The company offers its woman apparel under the La go go, Velwin, Sea To Sky, Jizhu, and idole brands. It also engages in the import and export of apparel, fabric, and accessories. The company provides its products directly to consumers through retail stores, as well as online stores at Tmall, Dangdang mall, JD.com, VIP.com, etc. As of March 31, 2022, it operated 848 stores in China. The company is based in Nanjing, the Peoples Republic of China.

Full EVKG Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this EVKG vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EVKG vs SCHDEVKG vs JEPIEVKG vs OEVKG vs KOEVKG vs MAINEVKG vs ABBVEVKG vs MRKEVKG vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.